GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » Debt-to-Equity

Eupraxia Pharmaceuticals (TSX:EPRX) Debt-to-Equity : 0.49 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals Debt-to-Equity?

Eupraxia Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$9.56 Mil. Eupraxia Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. Eupraxia Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was C$19.54 Mil. Eupraxia Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.49.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eupraxia Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

TSX:EPRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.68   Med: 0.41   Max: 4.72
Current: 0.49

During the past 7 years, the highest Debt-to-Equity Ratio of Eupraxia Pharmaceuticals was 4.72. The lowest was -0.68. And the median was 0.41.

TSX:EPRX's Debt-to-Equity is ranked worse than
74.47% of 1081 companies
in the Biotechnology industry
Industry Median: 0.15 vs TSX:EPRX: 0.49

Eupraxia Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Eupraxia Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals Debt-to-Equity Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial -0.68 -0.60 0.47 1.15 4.72

Eupraxia Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 1.50 0.90 4.72 0.49

Competitive Comparison of Eupraxia Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eupraxia Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's Debt-to-Equity falls into.


Eupraxia Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eupraxia Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(10.452 + 0) / 2.216
=4.72

Eupraxia Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(9.558 + 0) / 19.544
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals  (TSX:EPRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eupraxia Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eupraxia Pharmaceuticals (TSX:EPRX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » Debt-to-Equity
Comparable Companies
NEOE:MMED XCNQ:DTC TSXV:NGEN TSX:ONC TSX:BCT XCNQ:MSET TSXV:ARCH TSXV:MIR TSXV:DMT TSX:HBP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
EPRXF:USA
Address
201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Website
https://www.eupraxiapharma.com
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.